Dermatology
Skin clinical trials
Psoriasis, eczema, skin cancers, and other conditions of the skin and connective tissue. We’re tracking 5,186 recruiting studies in this area right now.
By phase
- Not applicable2,938
- Phase 2757
- Phase 1542
- Phase 3381
- Phase 1/Phase 2295
- Phase 4211
- Phase 2/Phase 362
Top conditions
- Breast Cancer1,226
- Melanoma184
- Rheumatoid Arthritis141
- Metastatic Breast Cancer140
- Atopic Dermatitis129
- Systemic Lupus Erythematosus126
- Breast Neoplasms120
- Triple Negative Breast Cancer117
- Colorectal Cancer93
- Ovarian Cancer92
- Psoriasis88
- Breast Carcinoma83
- Lung Cancer78
- Prostate Cancer70
- Rheumatoid Arthritis (RA)64
- Diabetic Foot Ulcer61
- Systemic Sclerosis60
- Cancer58
Leading sponsors
- Fudan University65
- M.D. Anderson Cancer Center52
- Memorial Sloan Kettering Cancer Center50
- Novartis Pharmaceuticals49
- Mayo Clinic42
- Assistance Publique - Hôpitaux de Paris41
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University37
- AstraZeneca36
- National Cancer Institute (NCI)35
- Second Affiliated Hospital, School of Medicine, Zhejiang University30
Where studies are running
- California416
- Arizona160
- Florida132
- Alabama130
- New York110
- Texas106
- Massachusetts93
- Maryland91
- Pennsylvania76
- North Carolina69
Recruiting studies5,186 total
- NCT06743126RecruitingPhase 3
IMA203 vs standard treatment for advanced skin cancer
This trial tests a new cell therapy called IMA203 against standard treatments for people with advanced melanoma (a type of skin cancer) that has spread or can't be removed. It may be an option if you have already tried certain treatments and your cancer has a specific cell marker (HLA-A*02:01).
Phoenix, ArizonaAges 18 years+ - NCT06905288Recruiting
Secukinumab for Ankylosing Spondylitis in Biologic-Free Patients
This study is looking at how well secukinumab works for people with ankylosing spondylitis in Korea who have never taken a biologic or JAK inhibitor before. It aims to understand if the drug helps control symptoms over a short period of time.
Jinju, Gyeongsangnam-doAges 18–40 - NCT07689591Recruiting
Non-invasive blood flow boost for heart attack patients
This trial tests a non-invasive method to improve blood flow in the arm during a heart attack. It may help reduce heart muscle damage before the standard artery-opening procedure.
Elâzığ, ElaziğAges 18–80 - NCT07621809RecruitingPhase 3
Ianalumab versus placebo for Sjögren's disease with high symptom burden
This study tests whether a new drug called ianalumab can reduce dry mouth and other symptoms in people with Sjögren's disease—a condition where the immune system attacks moisture-producing glands. Participants will receive either ianalumab or a placebo (inactive injection) over 52 weeks to see if the drug helps.
Peoria, ArizonaAges 18 years+ - NCT06789653Recruiting
Using age-related proteins in early breast cancer
This study is testing a new way to use proteins in your blood that change with age to better understand early-stage breast cancer. It may help doctors personalize your care.
Chapel Hill, North CarolinaAges 22–66 - NCT07220785RecruitingPhase 3
Testing mibavademab for generalized lipodystrophy in adults and children
This trial tests a new drug called mibavademab for people with generalized lipodystrophy, a condition where the body can't store fat properly, leading to problems like diabetes and high triglycerides. It aims to see if the drug safely improves these metabolic issues.
Ann Arbor, MichiganAges 2 years+ - NCT03673748RecruitingPhase 2
Mesenchymal stem cell treatment for lupus kidney inflammation
This trial tests whether donated (allogeneic) stem cells can improve lupus nephritis, a kidney complication of lupus. It is for adults whose lupus kidney disease has not responded well to standard treatments or has come back, and it requires signs of active disease.
Valladolid, ValladolidAges 18 years+ - NCT05136196RecruitingPhase 2
Cabozantinib plus nivolumab for advanced melanoma or head-neck cancer
This trial tests whether combining two immunotherapy medicines—cabozantinib and nivolumab—can shrink advanced melanoma or certain head-and-neck squamous cell cancers. It is mainly for people whose cancer has grown after prior PD-1 treatment.
Phoenix, ArizonaAges 18 years+ - NCT07631052RecruitingPhase 2
Low-dose Capecitabine for High-risk Early Breast Cancer
This study tests whether a low-dose chemotherapy pill called capecitabine can help prevent breast cancer from coming back in patients whose cancer shows signs of remaining disease (called MRD) despite standard treatment. The trial focuses on hormone-receptor-positive, HER2-negative breast cancers.
Toronto, OntarioAges 18 years+ - NCT03340506RecruitingPhase 4
Follow-on treatment study for dabrafenib and trametinib
This study lets people who finished a prior dabrafenib/trametinib trial (sponsored by Novartis or former GSK) continue those medicines if the study doctor thinks it will help. It mainly focuses on ongoing treatment benefit rather than testing a new drug.
Scottsdale, ArizonaAges 18–100 - NCT04772079RecruitingPhase 3
Test drug safety and effectiveness for youth plaque psoriasis
This study checks whether deucravacitinib works well and is safe in children and teens with moderate to severe plaque psoriasis. It also looks at drug levels in the body to help understand how the treatment behaves over time.
Ciudad Autonoma de Buenos Aires, Buenos AiresAges 4–18 - NCT06618287RecruitingPhase 1/Phase 2
Testing BMS-986507 for advanced lung and breast cancers
This study tests a new drug called BMS-986507, given in different combinations, for people with advanced solid tumors (lung cancer or breast cancer that has spread). It looks at safety, how the drug works in the body, and if it helps shrink tumors.
Birmingham, AlabamaAges 18 years+ - NCT06799065RecruitingPhase 1
Testing a new drug for advanced solid tumors
This trial tests ATX-295, a daily pill that blocks a protein called KIF18A, in people with advanced solid tumors, including ovarian cancer. It is for those whose cancer has grown after standard treatments or who cannot have standard therapy.
Aurora, ColoradoAges 18 years+ - NCT07182149RecruitingPhase 1
Testing a new drug for advanced solid tumors
This trial tests a new drug called NRM-823 for people with several types of advanced cancer that have stopped responding to standard treatments. The goal is to see if the drug is safe and how well it works.
Denver, ColoradoAges 18 years+ - NCT05827081RecruitingPhase 3
Ribociclib plus endocrine therapy for early breast cancer
This trial studies whether adding ribociclib to standard hormone (endocrine) therapy lowers the risk of breast cancer coming back in early-stage, hormone-receptor–positive cancer. It mainly looks at safety and how well the treatment controls cancer after surgery and (sometimes) prior hormone treatment.
Birmingham, AlabamaAges 18–100 - NCT07544056RecruitingPhase 2/Phase 3
BEBT-209 Plus Chemotherapy for Triple-Negative Breast Cancer
This study tests a new drug called BEBT-209 combined with chemotherapy (carboplatin and gemcitabine) in women with advanced triple-negative breast cancer that has spread or cannot be surgically removed. The goal is to see if this combination can slow or stop cancer growth better than standard treatments.
Guangzhou, GuangdongAges 18–75 - NCT07489573RecruitingPhase 4
Study of secukinumab for Chinese adults with moderate-to-severe HS
This study tests if a drug called secukinumab (a self-injected biologic) is safe and effective for adults with moderate-to-severe hidradenitis suppurativa (HS) in China. It may help reduce the number of painful HS lesions.
Guangzhou, GuangdongAges 18 years+ - NCT07768436RecruitingPhase 2
cmf chemotherapy for breast cancer in older adults
This trial tests a combination of three older chemotherapy drugs (cyclophosphamide, methotrexate, and fluorouracil, called CMF) for adults 70 and older with breast cancer. The goal is to see if this treatment is effective and well-tolerated in this age group.
Basking Ridge, New JerseyAges 70 years+ - NCT07769268Recruiting
Cream for treating dark spots on the face
This study tests a cosmetic cream to reduce dark spots on the face, including melasma and sun spots. It aims to see if the product improves the appearance of hyperpigmentation.
Osasco, São PauloAges 30–60 - NCT06585410RecruitingPhase 3
Cemiplimab injection for early-stage skin cancer
This trial tests a drug (cemiplimab) injected directly into early-stage skin cancer (squamous cell carcinoma) to see if it can shrink or cure the cancer before surgery. It may help patients avoid more extensive surgery or reduce the chance of the cancer coming back.
Phoenix, ArizonaAges 18 years+ - NCT07768228RecruitingPhase 2
L-carnitine for healing diabetic foot ulcers
This study tests whether a supplement called L-carnitine can help diabetic foot ulcers heal faster. It is for people with type 2 diabetes who have mild to moderate foot ulcers and neuropathy (nerve damage in the feet).
Cairo, Cairo GovernorateAges 30–75 - NCT06328777RecruitingPhase 2/Phase 3
Testing a new immune cell therapy for systemic sclerosis (scleroderma)
This trial tests a new treatment called CABA-201, which uses your own immune cells to target and calm the overactive immune system causing scleroderma. It aims to reduce symptoms and slow or stop the disease's progression.
New Haven, ConnecticutAges 18–75 - NCT06562270Recruiting
Teens with severe alopecia areata: treatment safety study
This study tracks the safety and effectiveness of alopecia areata treatments in teenagers aged 12-17. It helps doctors understand which treatments work best and are safest for young people with severe hair loss.
Waltham, MassachusettsAges 12–17 - NCT07767305Recruiting
Taping vs compression for breast swelling after radiation
This study compares two non-drug treatments for breast swelling (lymphedema) that can happen after breast-conserving surgery and radiation. It tests whether special tape (Kinesio Taping) works as well as compression therapy to reduce swelling and symptoms.
Tangshan, HebeiAges 18 years+
Common questions
- How many skin clinical trials are recruiting?
- Clin2 is tracking 5,186 recruiting dermatology studies from the U.S. registry right now, out of 8,234 we cover in this area in total.
- What does “Skin” cover here?
- Psoriasis, eczema, skin cancers, and other conditions of the skin and connective tissue. We group each study into skin based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a skin trial near me?
- Use the search to filter skin studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.